A first-in-human Phase 1 study of a CRISPR-based therapy has shown early signs that gene editing may help treat a rare metabolic disorder, according to researchers who presented the findings Sunday. The trial was designed first to assess safety, and investigators said the treatment appeared to be well tolerated.

Beyond safety, the early results also pointed to possible effectiveness, giving researchers cautious optimism that the approach could eventually offer a new option for patients with few existing treatments. As with any first-stage clinical trial, the findings are preliminary and need confirmation in larger and longer studies.

CRISPR has become one of the most closely watched tools in medicine because it can target genetic changes at the root of certain diseases. Scientists say its potential is especially important for rare disorders, where even small advances can make a major difference for patients and families.

Researchers emphasized that the work is still at an early stage, but the trial adds to growing evidence that gene-editing therapies may move from experimental science toward practical treatment in carefully selected conditions.